Paul L. Feldman

Paul L. Feldman is Chief Scientific Officer at Aktis Oncology, leading the development and execution of the company’s drug discovery technology platforms and the discovery of novel radiopharmaceutical compounds to treat cancer. Prior to joining Aktis, Paul was co-founder and CEO of Phoundry Pharmaceuticals which was acquired by Intarcia Therapeutics in 2015. He then spent 5 years at Intarcia on the executive management team as Head of Discovery and Translational Medicine leading the discovery and development of novel peptide therapeutics to treat metabolic disease. Before starting Phoundry, Paul spent more than 27 years at GlaxoSmithKline where he was part of the discovery of five approved drugs: ultrashort-acting analgesic opioid agonist remifentanil (Ultiva), HIV protease inhibitor, fosamprenavir (Lexiva/Telzir), HIV integrase inhibitors dolutegravir (Tivicay and component of Triumeq) and cabotegravir, a once-monthly injectable integrase inhibitor for HIV treatment approved as a combination with rilpivirine (Cabenuva), and the ultrashort-acting benzodiazepine, remimazolam (ByFavo).

Paul has more than 125 scientific disclosures including scientific articles, invited lectures, book chapters, patents, and poster presentations, and in 2014 he received the North Carolina Section of the American Chemical Society’s Distinguished Lecturer award. He is a member of Abbvie’s Chemistry Advisory Committee and serves on the board of the Chordoma Foundation.

Paul holds a PhD in chemistry from the University of California, Berkeley, and when not in the lab, he enjoys swimming, playing golf, and spending time with his family.